Over the past decade, sorafenib has been the only systemic agent with proven clinical
efficacy for patients with unresectable hepatocellular carcinoma (HCC). Recently, lenvatinib …

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death.
The immune-rich contexture of the HCC microenvironment makes this tumour an appealing …

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer.
Sorafenib, regorafenib, lenvatinib and cabozantinib are tyrosine kinase inhibitors (TKIs) that …

Background Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth
factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of …

Background A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–
associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion …

Hepatocellular carcinoma (HCC) can have viral or non-viral causes,,,–. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …

Background Cabozantinib has shown clinical activity in combination with checkpoint
inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab …

Summary Background Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown
promising antitumour activity in hepatocellular carcinoma as monotherapy and in …

The last 5 years have witnessed relevant advances in the systemic treatment of
hepatocellular carcinoma. New data have emerged since the development of the EASL …

379 Background: A single priming dose of T (anti-CTLA-4) added to D (anti-PD-L1) in the
STRIDE (Single T Regular Interval D) regimen, formerly T300+ D, showed encouraging …